BioVie plans $20M IPO for spinout tasked with developing liver disease drug
BioVie plans $20M IPO for spinout tasked with developing liver disease drug
Body unavailable. Use the original source.
BioVie plans $20M IPO for spinout tasked with developing liver disease drug
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.